Friday, October 9, 1998, the following correction is made:

On page 54532, in the first column, under the ADDRESSES caption, in the first and second lines from the bottom “Rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.” is corrected to read “5630 Fishers Lane, rm. 1061, Rockville, MD 20852.”

William K. Hubbard,
Associate Commissioner for Policy Coordination.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–0867]

Legal and Policy Interpretation of the Jurisdiction Under the Federal Food, Drug, and Cosmetic Act of the Food and Drug Administration and the Environmental Protection Agency Over the Use of Certain Antimicrobial Substances; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of policy interpretation; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice issued jointly by FDA and the Environmental Protection Agency (EPA) that appeared in the Federal Register of October 9, 1998 (63 FR 54532). The document set forth legal and policy interpretations of the Federal Food, Drug, and Cosmetic Act (FDCA) as they relate to the jurisdiction of EPA and FDA over antimicrobial substances used in or on food, including food-contact articles; discussed interpretations of certain terms in the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) and the implementing regulations relevant to the authority of the two agencies; provided a description of how EPA and FDA propose to clarify the post-Food Quality Protection Act (FQPA) regulatory authority over certain antimicrobial substances; and discussed how EPA and FDA plan to handle the review of petitions for antimicrobial substances that will remain under EPA’s jurisdiction, and for those that EPA proposes to return to FDA’s regulatory authority through EPA rulemaking. The document was published with an incorrect address for FDA’s Dockets Management Branch. This document corrects that error. EPA’s addresses remain the same.

EFFECTIVE DATE: October 9, 1998.


In FR Doc. 98–32025, appearing on page 54532 in the Federal Register of October 9, 1998, the following correction is made:

On page 54532, in the first column, the description of the use of certain antimicrobial substances is corrected.

William K. Hubbard,
Associate Commissioner for Policy Coordination.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98F–1034]

Solvay S.A.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Solvay S.A., has filed a petition proposing that the food additive regulations be amended to provide for the expanded safe use of naphthalene sulfonic acid-formaldehyde condensate, sodium salt as an emulsifier in vinylidene chloride copolymer or homopolymer coatings applied to polypropylene polymer films and polyethylene phthalate polymer films intended for use in contact with food.

FOR FURTHER INFORMATION CONTACT: Vir D. Anand, Center for Food Safety and Applied Nutrition (HFD–7), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

Olivia A. Pritzlaff, Center for Food Safety and Applied Nutrition.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–1036]

Vale Chemical Co., Inc., et al.; Proposal to Withdraw Approval of 13 New Drug Applications and 1 Abbreviated New Drug Application; Opportunity for a Hearing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for a hearing on the agency’s proposal to withdraw approval of 13 new drug applications (NDA’s) and 1 abbreviated new drug application (ANDA). The basis for the proposal is that the sponsors have repeatedly failed to file required annual reports for these applications.

DATES: Written requests for a hearing are due by January 4, 1999; data and information in support of the hearing request are due by February 1, 1999.

ADDRESSES: Requests for a hearing, supporting data, and other comments should be identified with Docket No. 98N–1036 and submitted to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Olivia A. Pritzlaff, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION: The holders of approved applications to market new drugs for human use are required to submit annual reports to FDA concerning each of their approved applications in accordance with § 314.81 (21 CFR 314.81). The holders of the applications listed in the following table have failed to submit the required...
annual reports and have not responded to the agency’s request by certified mail for submission of the reports.

<table>
<thead>
<tr>
<th>Application No.</th>
<th>Drug</th>
<th>Applicant</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 11–863</td>
<td>Flavist Cough Syrup</td>
<td>Boyle &amp; Co., 6330 Chalet Dr., Los Angeles, CA 90022.</td>
</tr>
<tr>
<td>NDA 50–067</td>
<td>Compopcillin-VK Chewable Wafers</td>
<td>Abbott Laboratories, 100 Abbott Park Rd., Abbott Park, IL 60064.</td>
</tr>
<tr>
<td>NDA 50–088</td>
<td>Unipen Injection</td>
<td>Wyeth-Ayerst Laboratories, P.O. Box 8299, Philadelphia, PA 19101–8299.</td>
</tr>
<tr>
<td>NDA 50–121</td>
<td>Compopcillin-VK Tablets</td>
<td>Do.</td>
</tr>
<tr>
<td>NDA 50–122</td>
<td>Compopcillin-V Chewable Wafers</td>
<td>Do.</td>
</tr>
<tr>
<td>NDA 50–129</td>
<td>Pen-Vee Suspension and Drops</td>
<td>Do.</td>
</tr>
<tr>
<td>NDA 50–189</td>
<td>Omnopen Tablets</td>
<td>Do.</td>
</tr>
<tr>
<td>NDA 50–197</td>
<td>Unipen Injection</td>
<td>Do.</td>
</tr>
<tr>
<td>NDA 50–305</td>
<td>Unipen Capsules</td>
<td>Do.</td>
</tr>
<tr>
<td>NDA 50–319</td>
<td>Omnopen Chewable Tablets</td>
<td>Do.</td>
</tr>
<tr>
<td>NDA 50–413</td>
<td>Geopen Diagnostic Susceptibility Powder</td>
<td>Do.</td>
</tr>
</tbody>
</table>

Therefore, notice is given to the holders of the applications listed in the table and to all other interested persons that the Director of the Center for Drug Evaluation and Research proposes to issue an order under section 505(e) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(e)) withdrawing approval of the applications and all amendments and supplements thereto on the ground that the applicants have failed to submit reports required under § 314.81.

In accordance with section 505 of the act and part 314 (21 CFR part 314), the applicants are hereby provided an opportunity for a hearing to show why the applications listed previously should not be withdrawn and an opportunity to raise, for administrative determination, all issues relating to the legal status of the drug products covered by these applications.

An applicant who decides to seek a hearing shall file: (1) On or before January 4, 1999, a written notice of participation and request for a hearing, and (2) on or before February 1, 1999, the data, information, and analyses relied on to demonstrate that there is a genuine and substantial issue of fact that requires a hearing. Any other interested person may also submit comments on this notice. The procedures and requirements governing this notice of opportunity for a hearing, notice of participation, and request for a hearing, information and analyses to justify a hearing, other comments, and a grant or denial of a hearing are contained in § 314.200 and in 21 CFR part 12.

The failure of an applicant to file a timely written notice of participation and request for a hearing, as required by § 314.200, constitutes an election by that applicant not to avail itself of the opportunity for a hearing concerning the proposal to withdraw approval of the applications and constitutes a waiver of any contentions concerning the legal status of the drug products. FDA will then withdraw approval of the applications and the drug products may not thereafter lawfully be marketed, and FDA will begin appropriate regulatory action to remove the products from the market. Any new drug product marketed without an approved NDA is subject to regulatory action at any time.

A request for a hearing may not rest upon mere allegations or denials, but must present specific facts showing that there is a genuine and substantial issue of fact that requires a hearing. Reports submitted to remedy the deficiencies must be complete in all respects in accordance with § 314.81. If the submission is not complete or if a request for a hearing is not made in the required format or with the required reports, the Commissioner of Food and Drugs will enter summary judgment against the person who requests the hearing, making findings and conclusions, and denying a hearing. All submissions under this notice of opportunity for a hearing must be filed in four copies. Except for data and information prohibited from public disclosure under 21 U.S.C. 331(j) or 18 U.S.C. 1905, the submissions may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday. This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 505 (21 U.S.C. 355)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82).

Dated: November 12, 1998.

Janet Woodcock,
Director, Center for Drug Evaluation and Research.

[FR Doc. 98–32069 Filed 12–1–98; 8:45 am] BILING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and